Showing results (1-10 of 267) with videos related to
Sort By:
Pageof 27
Hematology. American Society of Hematology. Education Program|February 20, 2015
Intermediate-risk acute myeloid leukemia therapy: current and futureKonstanze Döhner, Peter PaschkaHematology. American Society of Hematology. Education Program|December 10, 2013
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Peter Paschka, Konstanze DöhnerSeminars in Oncology|August 12, 2008
Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogeneticsVerena Gaidzik, Konstanze DöhnerCurrent Opinion in Hematology|May 27, 2009
Impact of new prognostic markers in treatment decisions in acute myeloid leukemiaRichard F Schlenk, Konstanze DöhnerJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysLars Bullinger, Konstanze Döhner, Hartmut DöhnerJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplicationPeter Paschka, Richard F Schlenk, Verena I Gaidzik, et al.Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.Experimental Hematology|December 21, 2010
TET genes: new players in DNA demethylation and important determinants for stemnessFabian Mohr, Konstanze Döhner, Christian Buske, et al.Expert Opinion on Drug Safety|June 28, 2021
A review of hydroxyurea-related cutaneous adverse eventsMartin Griesshammer, Kai Wille, Parvis Sadjadian, et al.Pageof 27